Daniel A. Dornbusch
Director Ejecutivo en Excision BioTherapeutics, Inc. .
Relaciones activas
| Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
|---|---|---|---|---|
| Stuart Peterson | M | - |
Excision BioTherapeutics, Inc.
 Excision BioTherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Excision BioTherapeutics, Inc. develops gene editing therapeutics for the treatment of life-threatening disease caused by viral infections. The firm focuses on Human Immunodeficiency Virus -1 therapeutics, JC Virus and Progressive Multifocal Leukoencephalopathy, Hepatitis B virus therapeutics, and CRISPR vaccinations?. The company was founded by David Rowe, Kamel Khalili, Thomas Malcolm, and Rob Simmons in 2015 and is headquartered in San Francisco, CA. | - |
| William Carson | M | 65 |
Excision BioTherapeutics, Inc.
Excision BioTherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Excision BioTherapeutics, Inc. develops gene editing therapeutics for the treatment of life-threatening disease caused by viral infections. The firm focuses on Human Immunodeficiency Virus -1 therapeutics, JC Virus and Progressive Multifocal Leukoencephalopathy, Hepatitis B virus therapeutics, and CRISPR vaccinations?. The company was founded by David Rowe, Kamel Khalili, Thomas Malcolm, and Rob Simmons in 2015 and is headquartered in San Francisco, CA. | 5 años |
| Ashok Krishnamurthi | M | - |
Excision BioTherapeutics, Inc.
Excision BioTherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Excision BioTherapeutics, Inc. develops gene editing therapeutics for the treatment of life-threatening disease caused by viral infections. The firm focuses on Human Immunodeficiency Virus -1 therapeutics, JC Virus and Progressive Multifocal Leukoencephalopathy, Hepatitis B virus therapeutics, and CRISPR vaccinations?. The company was founded by David Rowe, Kamel Khalili, Thomas Malcolm, and Rob Simmons in 2015 and is headquartered in San Francisco, CA. | - |
| Vasudev Bailey | M | - |
Excision BioTherapeutics, Inc.
Excision BioTherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Excision BioTherapeutics, Inc. develops gene editing therapeutics for the treatment of life-threatening disease caused by viral infections. The firm focuses on Human Immunodeficiency Virus -1 therapeutics, JC Virus and Progressive Multifocal Leukoencephalopathy, Hepatitis B virus therapeutics, and CRISPR vaccinations?. The company was founded by David Rowe, Kamel Khalili, Thomas Malcolm, and Rob Simmons in 2015 and is headquartered in San Francisco, CA. | - |
| Yamen Al-Hajjar | M | - |
Excision BioTherapeutics, Inc.
Excision BioTherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Excision BioTherapeutics, Inc. develops gene editing therapeutics for the treatment of life-threatening disease caused by viral infections. The firm focuses on Human Immunodeficiency Virus -1 therapeutics, JC Virus and Progressive Multifocal Leukoencephalopathy, Hepatitis B virus therapeutics, and CRISPR vaccinations?. The company was founded by David Rowe, Kamel Khalili, Thomas Malcolm, and Rob Simmons in 2015 and is headquartered in San Francisco, CA. | 3 años |
| Jenny Yip | F | - |
Excision BioTherapeutics, Inc.
Excision BioTherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Excision BioTherapeutics, Inc. develops gene editing therapeutics for the treatment of life-threatening disease caused by viral infections. The firm focuses on Human Immunodeficiency Virus -1 therapeutics, JC Virus and Progressive Multifocal Leukoencephalopathy, Hepatitis B virus therapeutics, and CRISPR vaccinations?. The company was founded by David Rowe, Kamel Khalili, Thomas Malcolm, and Rob Simmons in 2015 and is headquartered in San Francisco, CA. | 3 años |
Gráfico relacional
Relaciones con varias empresas
Estadísticas
| País | Relaciones | % del total |
|---|---|---|
| Estados Unidos | 6 | 100.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Daniel A. Dornbusch
- Red Personal
